Webinar on Pioglitazone The Untapped Diamond in Diabetes Care

Overview

The prevalence of type 2 diabetes has increased as a result of rising obesity rates and the aging population. Antidiabetic drug Pioglitazone alone or in combination with metformin, repaglinide, insulin, or sulphonylurea led to both long-term and short-term improvements in glycaemic control and serum lipid profiles. Additionally, several studies have shown that Pioglitazone does not raise cardiovascular risk and might exhibit some cardiovascular protective effects.